Related references
Note: Only part of the references are listed.HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
Giorgio Valabrega et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
The Prolyl Isomerase Pin1 Induces LC-3 Expression and Mediates Tamoxifen Resistance in Breast Cancer
Gwang Mo Namgoong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
Liane M. McGlynn et al.
CLINICAL CANCER RESEARCH (2009)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns et al.
CANCER CELL (2008)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Suleiman Massarweh et al.
CANCER RESEARCH (2008)
Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer
Greg Finn et al.
CURRENT CANCER DRUG TARGETS (2008)
Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT
Kristopher J. Stanya et al.
JOURNAL OF CELL BIOLOGY (2008)
Estrogen receptors and human disease
BJ Deroo et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Epigenetic information and estrogen receptor alpha expression in breast cancer
Laura Giacinti et al.
ONCOLOGIST (2006)
Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1)
P Yi et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice
H Yoshiji et al.
HEPATOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
R Clarke et al.
ONCOGENE (2003)
Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics
KP Lu
CANCER CELL (2003)
Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells
M Lee et al.
CANCER LETTERS (2003)
Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer
A Ryo et al.
JOURNAL OF CELL SCIENCE (2003)
Drug therapy: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice
BL Riggs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular determinants for the tissue specificity of SERMs
YF Shang et al.
SCIENCE (2002)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells
AS Oh et al.
MOLECULAR ENDOCRINOLOGY (2001)
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1
GM Wulf et al.
EMBO JOURNAL (2001)
Share Paper
